OCT 15, 2020 8:04 PM PDT

WHO Data Suggests Remdesivir Has No Effect on COVID-19 Infections

WRITTEN BY: Carmen Leitch

While the study has not yet been peer-reviewed, an international consortium has come to the conclusion that the antiviral drug remdesivir has little or no benefit for hospitalized COVID-19 patients. The study followed 11,266 adult patients in 405 hospitals in thirty countries. Of this group, 2,750 were treated with remdesivir, 954 received hydroxychloroquine, others received a drug treatment used for HIV, and just over 4,000 others were not given any of these medications.

Colorized scanning electron micrograph of a cell showing morphological signs of apoptosis, infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

The study assessed whether the drugs had any impact on mortality, when the patients needed ventilation, and the length of hospitalized patients' stays. In a statement, the World Health Organization (WHO) noted that the research did not assess whether any of these drugs have a preventive effect or might be useful for people that are not hospitalized.

This study confirms others that have indicated that hydroxychloroquinine has no beneficial effect.

Previous work has indicated that remdesivir can benefit patients that are on ventilators but not mild cases; in other words, the patient's condition has to be dire for remdesivir to work, according to other findings.

In a statement, the maker of remdesivir, GIlead, pushed back against WHO's data.

"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir). We are concerned that the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion," Gilead said.

Earlier this year, the National Institutes of Health reported that a clinical trial involving patients hospitalized with COVID-19 and treated with remdesivir had shown positive results, but those benefits were modest. The trial suggested that patients on remdesivir would recover within around eleven days compared to fifteen days for people taking a placebo. The work also indicated that it may reduce mortality; 8.0 percent of people on remdesivir died, while 11.6 percent on placebo died. However, the trial was criticized for not including a diverse cohort of participants.

The NIH is currently conducting a study to investigate whether remdesivir plus interferon beta-1a is effective at treating COVID-19.

Sources: medRxiv, WHO, NIH

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUL 22, 2020
Infographics
The Science of Sourdough
JUL 22, 2020
The Science of Sourdough
During the coronavirus stay-at-home order, many people have taken up the art of making sourdough bread and have learned ...
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
SEP 01, 2020
Cell & Molecular Biology
Smell Cells Are Especially Good at Fighting the Flu
SEP 01, 2020
Smell Cells Are Especially Good at Fighting the Flu
All over the body, cells line organs and vessels, forming protective barriers. But pathogens like the flu have gained th ...
SEP 09, 2020
Microbiology
Changing How We Think of Drug Resistance in Fungi
SEP 09, 2020
Changing How We Think of Drug Resistance in Fungi
It's been estimated that fungal infections cause more than one million deaths worldwide, and many more are affected.
SEP 09, 2020
Cell & Molecular Biology
Why Liver Gene Therapies Have Not Worked & How to Improve Them
SEP 09, 2020
Why Liver Gene Therapies Have Not Worked & How to Improve Them
Diseases that are caused by errors in a gene might be cured if we could correct those errors, or genetic mutations.
SEP 23, 2020
Cell & Molecular Biology
How Heparan Sulfate Helps SARS-CoV-2 Enter Cells
SEP 23, 2020
How Heparan Sulfate Helps SARS-CoV-2 Enter Cells
In order to infect a cell, the SARS-CoV-2 virus has to find a way in. It can use receptors on the surface of cells that ...
Loading Comments...